A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
Recruiting · NCT07460375 · Registry updated 2026-07-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2026-07-24 | NCT07460375 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AntibodyChem Biosciences, Inc. | 2 |
| LigaChem Biosciences, Inc. | 4 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center | Seoul | South Korea | 338 |
| Mass General Hospital | Boston | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Medical University of South Carolina | Charleston | United States | 1 |
| Princess Margaret Hospital | Toronto | Canada | 1 |
| Samsung Medical Center | Seoul | South Korea | 375 |
| Seoul National University Hospital | Seoul | South Korea | 393 |
| START New York - Long Island | Lake Success | United States | 1 |